Cerity Partners
SUPN icon

Cerity Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Cerity Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,355
Closed -$304K – 3010
2025
Q3 		$304K Buy
+6,355
New +$256K ﹤0.01% 2273
2024
Q2 		– Sell
-6,123
Closed -$209K – 2400
2024
Q1 		$209K Buy
+6,123
New +$182K ﹤0.01% 2093
2023
Q2 		– Sell
-1,067
Closed -$431K – 1935
2023
Q1 		$431K Buy
+1,067
New +$41K ﹤0.01% 1359
2019
Q4 		– Sell
-8,899
Closed -$245K – 570
2019
Q3 		$245K Sell
8,899
-309
-3% -$9.16K 0.01% 424
2019
Q2 		$304K Buy
+9,208
New +$315K 0.02% 398

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerity Partners's SUPN Position: Q4 2025 in Review

Cerity Partners sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 6,355 shares — an estimated $304K sold.

Cerity Partners first reported a position in SUPN in Q2 2019 and held it in 5 quarters. The position peaked at $431K in Q1 2023. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • Cerity Partners reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Cerity Partners sold 6,355 Supernus Pharmaceuticals shares in Q4 2025, an estimated $304K.
  • Cerity Partners first reported a position in Supernus Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • Cerity Partners's Supernus Pharmaceuticals position peaked at $431K in Q1 2023.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Cerity Partners's 13F filing for Q4 2025, filed 11 Feb 2026.